



Associations of dietary intakes of vitamins B₁ and B₃ with risk of mortality from CVD among Japanese men and women: the Japan Collaborative Cohort study

Chengyao Tang¹, Ehab Salah Eshak^{2,3}, Kokoro Shirai¹, Akiko Tamakoshi⁴ and Hiroyasu Iso^{1*}

¹Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan

²Public Health and Community Medicine Department, Faculty of Medicine, Minia University, Minia, Egypt

³Advanced Clinical Epidemiology, Medical Data Science, Public Health, Graduate School of Medicine, Osaka University, Osaka, Japan

⁴Public Health, Department of Social Medicine, Faculty of Medicine, Hokkaido University, Hokkaido, Japan

(Submitted 2 August 2021 – Final revision received 7 March 2022 – Accepted 8 April 2022 – First published online 25 April 2022)

Abstract

The evidence on the association between B vitamins and the risk of CVD is inconclusive. We aimed to examine the association of dietary vitamins B₁ and B₃ intakes with risk of CVD mortality among 58 302 Japanese men and women aged 40–79 years participated in the Japan Collaborative Cohort (JACC) study. The Cox proportional hazard model estimated the hazard ratios (HR) and 95% CI of CVD mortality across increasing energy-adjusted quintiles of dietary vitamins B₁ and B₃ intakes. During 960 225 person-years of follow-up, we documented a total of 3371 CVD deaths. After adjustment for age, sex, and other CVD risk factors, HR of mortality from ischemic heart disease, myocardial infarction, and heart failure in the highest v. lowest vitamin B₁ intake quintiles were 0.57 (95% CI 0.40, 0.80; $P_{\text{for trend}} < 0.01$), 0.56 (95% CI 0.37, 0.82; $P_{\text{for trend}} < 0.01$), and 0.65 (95% CI 0.45, 0.96; $P_{\text{for trend}} = 0.13$). The multivariable HR of myocardial infarction mortality in the highest v. lowest vitamin B₃ intake quintiles was 0.66 (95% CI 0.48, 0.90; $P_{\text{for trend}} = 0.02$). A tendency towards a reduced risk of haemorrhagic stroke mortality was observed with a higher dietary intake of vitamin B₃ (HR: 0.74 (95% CI 0.55, 1.01)) but not vitamin B₁. In conclusion, higher dietary intakes of vitamins B₁ and B₃ were inversely associated with mortality from ischemic heart disease and a higher dietary intake of vitamin B₁ was inversely associated with a reduced risk of mortality from heart failure among Japanese men and women.

Key words: Dietary vitamin B₁; Dietary vitamin B₃; CVD; Cohort study

Vitamin B complex exerts its function in energy metabolism, immune function and DNA synthesis, methylation and repair⁽¹⁾. Vitamin B deficiency has been associated with cardiovascular disorders, particularly in ageing population⁽¹⁾.

Among the B complex group, vitamin B₁ and vitamin B₃ come mainly from cereals, beef and pork, seeds and nuts, and yeast⁽²⁾. Vitamin B₁ deficiency results in beriberi, a neurological and cardiovascular disorder⁽³⁾, while deficient vitamin B₃ can cause pellagra-induced dilated cardiomyopathy⁽⁴⁾. The potential positive impacts of vitamin B₁ and B₃ on cardiovascular health were suggested in several animal studies and supplemental clinical trials. In a Langendorff perfused rat hearts, vitamin B₁ exerted protective effects against myocardial ischaemic injury via maintaining mitochondrial size and ATP levels⁽⁵⁾. A randomised controlled trial on chronic heart failure patients who used diuretics reported that 300 mg/d of vitamin B₁ supplementation for 28 d increased the left ventricular ejection fraction by 3.9%⁽⁶⁾. On the other hand, 1500–2000 mg/d vitamin B₃ supplementation

was shown to decrease LDL-cholesterol, TAG and lipoprotein(a) levels, while increasing HDL-cholesterol level^(7,8). A meta-analysis of clinical trials suggested that vitamin B₃ supplements significantly reduced major coronary events, stroke and other cardiovascular events⁽⁹⁾.

Despite the abundant evidence on cardiovascular beneficial effects of vitamins B₁ and B₃ from animal studies^(3,10,11) and supplemental clinical trials^(12,13), no human observational studies so far have investigated the associations of dietary vitamins B₁ and B₃ intakes with risk of CVD. Previous studies indicated that food sources rich in vitamins B₁ and B₃ such as fish/seafood and vegetables were associated with a reduced risk of mortality from CVD^(14,15). Yet, the evidence on dietary vitamin B complex/CVD association was mainly directed to vitamins B₂, B₆, B₁₂ and folate, while the effects of dietary vitamins B₁ and B₃ intakes were not studied. Another issue is that most of the clinical trials on cardiovascular risk used high dosages of vitamin B₁ (200–300 mg/d) and B₃ supplement (1500–2000 mg/d), while the RDA of

Abbreviation: JACC, Japan Collaborative Cohort.

* **Corresponding author:** Hiroyasu Iso, email iso@pbhel.med.osaka-u.ac.jp

vitamin B₁ for Japanese men and women aged 50–69 years were 1.3 and 1.1 mg/d, respectively, and RDA of vitamin B₃ were 14 and 11 mg/d, respectively⁽¹⁶⁾. Among Japanese men aged 30–49 years, the estimated average requirement and RDA were 1.2 and 1.4 mg/d, respectively, for vitamin B₁, and those for vitamin B₃ were 13 and 15 mg/d, respectively. Among Japanese women aged 30–49 years, the corresponding estimated average requirement was 0.9 and 1.1 mg/d, and RDA was 10 and 12 mg/d. The estimated average requirement and RDA of vitamins B₁ and B₃ in Japanese men and women aged over 70 years were even less than any other age groups⁽¹⁶⁾. Not all individuals prefer or can afford vitamin supplements for their health; thus, improving the dietary vitamin intakes is more achievable and acceptable by the general population. Therefore, after established effects of supplementary intakes of vitamins B₁ and B₃ have been determined, studying the cardiovascular impacts of dietary intakes of vitamins B₁ and B₃ is now warranted. Owing to the research gap in the field of epidemiology and similar food sources of vitamins B₁ and B₃, their associations with CVD mortality were hypothesised in the present study. Therefore, we aimed to investigate the associations of dietary vitamins B₁ and B₃ intakes with risk of CVD mortality, which was considered as a proxy of CVD incidence risk, among Japanese men and women using the Japan Collaborative Cohort (JACC) study, a nationwide, community-based prospective cohort study.

Methods

Study population and baseline data

Under the sponsorship of the Ministry of Education, Sports, and Science, the JACC study had the baseline survey (1988–1990) of 110 585 Japanese men (*n* 46 395) and women (*n* 64 190) aged 40–79 years from forty-five areas all over Japan. A detailed cohort profile of the JACC study was published previously⁽¹⁷⁾. Data on the baseline lifestyle and participants' characteristics, including demographic data, medical history of chronic diseases, diabetes mellitus, hypertension, smoking, alcohol consumption, exercise, diet and other items, were compiled via a self-administered questionnaire (online Supplementary Methods). The questionnaire included a validated forty-food item/FFQ which was distributed in thirty-two areas; therefore, we started with 86 401 subjects from those thirty-two areas. After the exclusion of non-respondents to FFQ (*n* 24 614), we further excluded those who reported a medical history of CVD or cancer (*n* 3142) and those who had implausible energy intakes defined as outliers of mean \pm three standard deviations (*n* 343). Finally, a total of 58 302 individuals were eligible for the present study (22 989 men and 35 313 women) (online Supplementary Fig. S1). Written informed consent was acquired from community leaders or the individuals. The protocol of JACC study was approved by the Medical Ethical Committees of Nagoya University School of Medicine.

Dietary intake assessment

The participants were required to choose one from five frequency responses to describe the usual consumption frequency

of forty food and beverage items over the past 12 months without specification of the portion size. The five responses were rarely, 1–2 times/month, 1–2 times/week, 3–4 times/week and almost every day. These frequencies were transformed into weekly consumption scores of 0, 0.38, 1.5, 3.5 and 7.0 per week, respectively^(17,18). A validation study among eighty-five individuals using four 3-d weighed dietary records over a 1-year period as a reference standard determined the portion size for each food and validated the FFQ intakes. The amount of nutrients in each food was calculated by multiplying the weekly consumption scores by the estimated portion size. The values of vitamins B₁ and B₃ and other nutrients from each food category were calculated according to the Standardised Tables of Food Composition, 5th revised version⁽¹⁹⁾ which listed the nutrients content in 100 mg of different foods. Thus, the total vitamins B₁ and B₃ intakes were calculated by summing their intakes from all over the foods in the FFQ. The details of computation of nutrient intakes from FFQ⁽¹⁸⁾ and the accuracy of food composition tables in Japan^(20,21) were published previously. The Spearman rank correlation coefficients for vitamins B₁ and B₃ intakes between the FFQ and the four 3-d dietary records were 0.36 and 0.32, respectively, after energy adjustment⁽²²⁾. The energy-adjusted mean \pm standard deviation intakes in mg/d from weighed dietary record and FFQ were 1.08 (SD 0.20) and 0.71 (SD 0.20) for vitamin B₁, but the respective values for vitamin B₃ were not reported⁽¹⁸⁾.

Mortality surveillance

The investigators annually or biannually confirmed the dates and causes of death in each area⁽¹⁷⁾. The International Classification of Diseases, 10th revision (ICD10) codes were applied to determine the underlying causes of death. In this study, our primary outcome was the total CVD mortality (ICD I01-I99). Cause-specific outcomes included mortalities from total stroke (ICD I60-I69), haemorrhagic stroke (ICD I60-I61), ischaemic stroke (ICD I63.0-I63.9), ischaemic heart disease (ICD I20-I25), myocardial infarction (ICD I20) and heart failure (ICD I50). This death certificate ascertainment was applied to all deaths within our cohort except for deaths that occurred outside of the original resident areas, which were treated as censored cases.

Statistical analysis

Energy-adjusted dietary intakes of vitamins B₁ and B₃ were categorised into five categorical groups (quintiles). The significance of differences in means or proportions of participants' characteristics and known risk factors of CVD in each quintile was tested by the ANCOVA and χ^2 test.

Person-years of follow-up were calculated from the baseline in 1988–1990 to their first endpoint in this follow-up as follows: death, moving out or the end of follow-up, whichever came first. The follow-up for mortality from CVD was conducted until 31 December 2009 in general; however, in four areas the follow-up was stopped until 31 December 1999, in another four areas until 31 December 2003 and in two areas until 31 December 2008⁽¹⁷⁾. The Cox proportional hazard model was applied to calculate crude and multivariable-adjusted hazard ratios and 95% CI for risk of mortality from CVD during the follow-up period



(1988–2009) across quintiles of dietary vitamins B₁ and B₃ intakes. We confirmed no violation of the Cox proportional hazard assumption because there were no significant interactions between the categorical rank variables of dietary vitamins B₁ and B₃ intakes and a function of survival time for all the tested outcomes. Multiplicative interactions of vitamins B₁ and B₃ with sex were tested to decide on presenting the data sex specifically or for combined men and women. The hypothesised confounders included age, sex, medical history of hypertension and diabetes, smoking status, ethanol intake, hours of sports, hours of walking, quintiles of BMI, years of education, perceived mental stress, daily utilisation of multivitamin supplementation, energy-adjusted quintiles of Na and SFA intakes and quintiles of total energy intake. Details of these factors are given in online Supplementary Methods.

We assigned the median values to each quintile of vitamins B₁ and B₃ and tested their significance to calculate the trends across quintiles of vitamins B₁ and B₃ intakes. We further conducted a sensitivity analysis by excluding those who died within first 3 years of follow-up to avoid potential as-yet-undiagnosed diseases at baseline. All probability values for statistical test were two-tailed, and $P < 0.05$ was regarded as statistically significant. We applied the SAS statistical package (Version 9.4; SAS Institute Inc.) for statistical analysis.

Results

As shown in Table 1, participants in the highest quintile of both vitamins B₁ and B₃ intake were older, less educated, under less mental stress, had more walking time, had higher BMI and were less likely to be current smoker and to have a history of hypertension or diabetes. They also used multivitamin supplementation less frequently and consumed less alcohol but consumed more Na, SFA and total energy when compared with those in the lowest quintile. In this study, sources of vitamin B₁ were 31 % from pork, 17 % from vegetables, 10 % from fish and 7 % from potatoes, while sources of vitamin B₃ were 43 % from fish, 13 % from vegetables, 8 % from pork, 7 % from coffee and 6 % from green tea (data not shown in tables).

Since no interaction with sex was observed for the association of vitamins B₁ and B₃ with CVD and specific endpoints, we combined the results of men and women in the main analyses. During 960 225 person-years of follow-up for 58 302 participants, we documented a total of 3371 deaths due to CVD, among whom there were 1504 deaths due to stroke (549 of which were due to haemorrhagic stroke and 816 of which were due to ischaemic stroke), 699 deaths were due to ischaemic heart disease (including 524 deaths due to myocardial infarction) and 564 deaths were due to heart failure.

As shown in Table 2, the dietary intake of vitamin B₁ was not associated with mortality from total stroke or its subtypes. On the other hand, a higher dietary vitamin B₁ intake was associated with the reduced risk of ischaemic heart disease, myocardial infarction and total CVD; hazard ratios were 0.57 (95 % CI 0.40, 0.80; $P_{\text{for trend}} < 0.01$), 0.56 (95 % CI 0.37, 0.82; $P_{\text{for trend}} < 0.01$) and 0.85 (95 % CI 0.73, 0.99; $P_{\text{for trend}} = 0.03$), respectively, in the highest *v.* lowest intake quintile. Moreover, the

multivariable-adjusted hazard ratio of heart failure mortality in the highest *v.* lowest intake quintiles was 0.65 (95 % CI 0.45, 0.96; $P_{\text{for trend}} = 0.13$).

For vitamin B₃, as shown in Table 3, there was no association with the mortality from stroke or heart failure. Statistically significant inverse trends in risks of mortality from total CVD, haemorrhagic stroke, ischaemic heart disease and myocardial infarction were observed in the age- and sex-adjusted model. However, after the multivariate adjustment, these associations were weakened; the multivariable-adjusted hazard ratios in the highest *v.* lowest quintiles of dietary vitamin B₃ were 0.90 (95 % CI 0.80, 1.03; $P_{\text{for trend}} = 0.13$) for total CVD mortality, 0.74 (95 % CI 0.55, 1.01; $P_{\text{for trend}} = 0.16$) for haemorrhagic stroke, 0.79 (95 % CI 0.60, 1.04; $P_{\text{for trend}} = 0.05$) for ischaemic heart disease and 0.66 (95 % CI 0.48, 0.90; $P_{\text{for trend}} = 0.02$) for myocardial infarction.

There were 456 participants who died within the first 3 years of follow-up, and excluding those subjects yielded no substantial changes in the associations of vitamins B₁ and B₃ with mortality from ischaemic heart disease and myocardial infarction (online Supplementary Table S1).

Discussion

In this large community-based prospective cohort study of Japanese men and women, higher dietary intakes of vitamins B₁ and B₃ were associated with reduced risks of mortality from total CVD, ischaemic heart disease and myocardial infarction. Neither dietary vitamin B₁ nor vitamin B₃ intake was associated with the mortality risk of stroke, except for a tendency towards a reduced risk of haemorrhagic stroke with a higher dietary vitamin B₃ intake. Moreover, a higher dietary intake of vitamin B₁ was associated with a reduced risk of heart failure.

As far to our knowledge, the present study is the first to investigate associations of dietary vitamins B₁ and B₃ intakes with risk of CVD mortality despite the abundant evidence from animal studies and clinical trials on vitamins B₁ and B₃ supplements. Vitamins B₁ and B₃ in animal studies and human clinical trials showed protective effects against myocardial ischaemia.

One study on dogs showed that administration of vitamin B₁ decreased the metabolic needs of the heart, which was manifested as reduced myocardial oxygen consumption, mean peripheral pressure and left ventricular pressure up to 45, 25 and 10 % respectively⁽¹¹⁾. A clinical trial on ten healthy adults and ten type 2 diabetes patients reported improvements in the brachial artery vasoactivity and the endothelium-dependent vasodilatation in both groups after a week of daily intravenous administration of 100 mg of vitamin B₁⁽²³⁾. Another randomised, cross-over and investigator-blinded trial on twenty adult healthy volunteers indicated the flow-mediated dilatation of the brachial artery was reduced by 50 % of its baseline diameter after smoking one cigarette, and the reduction in the flow-mediated vasodilatation with smoking one cigarette was only 25 % when 1050 mg/d oral benfotiamine was administered for 3 d before the experiment⁽²⁴⁾.

On the other hand, vitamin B₃ is a candidate to lower the risk of CVD as it is known to decrease LDL-cholesterol, TAG and

Table 1. Participants' characteristics and dietary variables according to quintiles of dietary vitamins B₁ and B₃ intakes at baseline in a cohort of 22 989 men and 35 313 women with a total of 3371 CVD mortality cases

Quintile	1 (low)	2	3	4	5 (high)	<i>P</i> for difference
No. at risk	11 660	11 661	11 660	11 661	11 660	
Vitamin B ₁						
Vitamin B ₁ intake, mg/d	0.8	0.9	1.0	1.0	1.2	< 0.001
Female, %	21.1	57.2	69.9	76.3	78.3	< 0.001
Age, years	54.8	56.3	56.3	56.6	56.8	< 0.001
BMI, kg/m ²	22.7	22.8	22.8	23.0	22.9	< 0.001
Ethanol intake, g/d	42.8	21.5	17.3	14.1	12.8	< 0.001
Current smoker, %	52.4	26.8	18.1	14.1	12.7	< 0.001
History of hypertension, %	20.8	20.7	20.2	19.8	18.4	< 0.001
History of diabetes, %	5.6	4.9	4.5	4.2	3.5	< 0.001
Sports ≥ 5 h/week, %	5.6	5.3	5.1	5.2	5.7	0.14
Walking ≥ 1 h/day, %	47.7	48.4	49.2	52.1	56.4	< 0.001
> 18 years education, %	16.7	13.9	13.6	12.9	11.8	< 0.001
High mental stress, %	26.2	23.3	21.0	20.9	20.2	< 0.001
Multivitamin supplementation, %	3.9	3.4	3.0	3.2	3.0	< 0.001
Na intake, mg/d	1498.4	1779.6	2005.3	2221.4	2515.4	< 0.001
SFA intake, mg/d	8.0	9.2	9.8	10.4	11.9	< 0.001
Total energy intake, kcal/d	1665.6	1446.3	1457.5	1512.2	1680.2	< 0.001
Vitamin B ₃ intake, mg/d	15.2	17.3	18.1	18.9	20.4	< 0.001
Vitamin B ₃						
Vitamin B ₃ intake, mg/d	14.4	16.7	17.9	19.2	21.5	< 0.001
Female, %	30.1	59.6	67.4	71.3	74.4	< 0.001
Age, years	55.7	56.2	56.1	56.2	56.7	< 0.001
BMI, kg/m ²	22.7	22.8	22.8	22.9	23.0	< 0.001
Ethanol intake, g/d	42.3	23.8	19.7	16.9	13.5	< 0.001
Current smoker, %	42.9	24.5	20.7	18.8	17.6	< 0.001
History of hypertension, %	22.0	20.8	19.6	19.5	18.0	< 0.001
History of diabetes, %	5.8	4.6	4.1	4.1	4.1	< 0.001
Sports ≥ 5 h/week, %	5.8	4.7	5.2	5.5	5.7	0.88
Walking ≥ 1 h/day, %	47.5	47.7	50.5	52.0	56.0	< 0.001
> 18 years education, %	17.5	14.2	13.1	12.6	11.5	< 0.001
High mental stress, %	24.8	23.1	22.2	21.0	20.5	< 0.001
Multivitamin supplementation, %	4.2	3.6	2.9	3.0	3.0	< 0.001
Na intake, mg/d	1678.5	1894.9	2016.8	2113.8	2316.1	< 0.001
SFA intake, mg/d	8.8	9.6	9.8	10.1	10.9	< 0.001
Total energy intake, kcal/d	1639.1	1461.6	1478.0	1536.6	1646.6	< 0.001
Vitamin B ₁ intake, mg/d	0.8	0.9	1.0	1.0	1.1	< 0.001

lipoprotein(a) levels, while increasing HDL-cholesterol level⁽⁷⁾. Among 8341 American men aged 30–64 years from Coronary Drug Project with previous myocardial infarction, 3000 mg/d vitamin B₃ *v.* placebo for a follow-up of 15 years reduced 14% of the mortality from total CVD and 26% of the mortality from ischaemic attack after a mean follow-up of 15 years⁽¹²⁾. Additionally, a meta-analysis of twenty-three randomised controlled trials including 39 195 participants reported a pooled risk ratio (CI) of mortality from fatal or non-fatal myocardial infarction (OR: 0.93; 95% CI 0.87, 1.00) for vitamin B₃ (median dose: 2 g/d; median duration: 11.5 months) *v.* control⁽¹³⁾. Another meta-analysis of eleven randomised controlled trials including 6616 participants showed vitamin B₃ (250–3000 mg/d) significantly decreased major coronary events (OR: 0.75; 95% CI 0.65, 0.96), stroke (OR: 0.74; 95% CI 0.59, 0.92) and any cardiovascular events (OR: 0.73; 95% CI 0.63, 0.85)⁽⁹⁾. In a recent meta-analysis of seventeen clinical trials including 35 760 participants, vitamin B₃ therapy (100–4000 mg/d) was shown to be associated with reduction of acute coronary syndrome (relative risk: 0.74; 95% CI 0.58, 0.96) and stroke (relative risk: 0.74; 95% CI 0.59, 0.94)⁽²⁵⁾. A meta-analysis including 9959 subjects reported similar results for total CVD events (OR: 0.66; 95% CI

0.49, 0.89) and major coronary events (OR: 0.75; 95% CI 0.59, 0.96) but not for stroke (OR: 0.88; 95% CI 0.50, 1.54)⁽²⁶⁾. Another meta-analysis of thirteen trials of vitamin B₃ treatment demonstrated a significant reduced risk of non-fatal myocardial infarction (risk ratio: 0.85; 95% CI 0.73, 1.00), a weak association with CVD mortality (risk ratio: 0.91; 95% CI 0.81, 1.02) and no association with stroke (risk ratio: 0.89; 95% CI: 0.72, 1.10)⁽²⁷⁾.

The mechanisms by which vitamins B₁ and B₃ might be protective against CVD mortality, especially those from ischaemic heart disease could be summarised here. Vitamin B₁ deficiency was highly prevalent in patients with type 2 diabetes⁽²⁸⁾, which is considered as one of the risk factors for ischaemic heart disease. In addition, vitamin B₁ inhibits human infragenicular accelerated proliferation of arterial smooth muscle cells and mitigates atherosclerosis and endothelial dysfunction⁽²⁹⁾. Another potential mechanism might be the protective effects of vitamin B₁ against ischaemic injury via reducing the metabolic needs of heart⁽⁵⁾. For vitamin B₃, the reduced CVD risk may be involved in the favourable effects of vitamin B₃ on lipid metabolism^(7,8). Vitamin B₃ also has anti-inflammatory properties demonstrated by lowering C-reactive protein lipoprotein-associated phospholipase A2,

Table 2. CVD mortality according to quintiles of vitamin B₁ intake (Hazard ratios and 95 % confidence intervals)

	Q1 (low)	Q2		Q3		Q4		Q5 (high)		<i>P</i> _{for trend}
		HR	95 % CI	HR	95 % CI	HR	95 % CI	HR	95 % CI	
Total <i>n</i>	11 660	11 661		11 660		11 661		11 660		
Person-years	182 559	185 652		192 066		197 635		202 313		
CVD										
No. of case	675	701		651		674		670		
Age- and sex-adjusted HR (95% CI)	1.00	0.92	0.83, 1.03	0.86	0.77, 0.96	0.83	0.75, 0.93	0.80	0.71, 0.89	< 0.001
Multivariable HR (95% CI) ¹	1.00	0.92	0.83, 1.03	0.86	0.77, 0.96	0.84	0.75, 0.93	0.80	0.71, 0.89	< 0.001
Multivariable HR (95% CI) ²	1.00	1.01	0.90, 1.14	0.93	0.82, 1.05	0.90	0.79, 1.02	0.86	0.75, 0.98	0.01
Multivariable HR (95% CI) ³	1.00	0.98	0.87, 1.11	0.88	0.76, 1.00	0.85	0.74, 0.98	0.85	0.73, 0.99	0.03
Stroke										
No. of case	284	300		290		313		317		
Age- and sex-adjusted HR (95% CI)	1.00	0.94	0.80, 1.11	0.91	0.77, 1.08	0.93	0.78, 1.10	0.91	0.76, 1.07	0.27
Multivariable HR (95% CI) ¹	1.00	0.94	0.79, 1.11	0.92	0.77, 1.09	0.93	0.78, 1.10	0.90	0.76, 1.07	0.28
Multivariable HR (95% CI) ²	1.00	1.11	0.92, 1.33	1.08	0.89, 1.31	1.10	0.90, 1.34	1.07	0.87, 1.30	0.68
Multivariable HR (95% CI) ³	1.00	1.06	0.87, 1.28	1.00	0.81, 1.23	1.02	0.82, 1.27	1.05	0.83, 1.33	0.77
Haemorrhagic stroke										
No. of case	119	105		101		104		120		
Age- and sex-adjusted HR (95% CI)	1.00	0.79	0.60, 1.04	0.74	0.56, 0.97	0.71	0.54, 0.95	0.79	0.60, 1.04	0.09
Multivariable HR (95% CI) ¹	1.00	0.79	0.60, 1.04	0.74	0.56, 0.98	0.73	0.55, 0.96	0.80	0.61, 1.05	0.15
Multivariable HR (95% CI) ²	1.00	0.94	0.70, 1.27	0.89	0.65, 1.23	0.88	0.64, 1.22	0.97	0.70, 1.33	0.93
Multivariable HR (95% CI) ³	1.00	0.91	0.66, 1.24	0.85	0.61, 1.19	0.84	0.59, 1.21	1.02	0.70, 1.50	0.74
Ischaemic stroke										
No. of case	141	169		161		175		170		
Age- and sex-adjusted HR (95% CI)	1.00	1.05	0.84, 1.32	1.03	0.82, 1.30	1.04	0.83, 1.31	0.99	0.79, 1.25	0.89
Multivariable HR (95% CI) ¹	1.00	1.04	0.83, 1.31	1.03	0.81, 1.30	1.03	0.82, 1.30	0.98	0.77, 1.23	0.83
Multivariable HR (95% CI) ²	1.00	1.22	0.95, 1.57	1.18	0.90, 1.54	1.18	0.90, 1.54	1.12	0.85, 1.48	0.62
Multivariable HR (95% CI) ³	1.00	1.13	0.87, 1.47	1.06	0.80, 1.41	1.08	0.80, 1.45	1.06	0.77, 1.47	0.99
Ischaemic heart disease										
No. of case	174	163		134		122		106		
Age- and sex-adjusted HR (95% CI)	1.00	0.90	0.72, 1.11	0.75	0.60, 0.95	0.65	0.51, 0.83	0.55	0.43, 0.71	< 0.001
Multivariable HR (95% CI) ¹	1.00	0.89	0.72, 1.11	0.75	0.60, 0.95	0.65	0.51, 0.83	0.55	0.42, 0.71	< 0.001
Multivariable HR (95% CI) ²	1.00	0.90	0.71, 1.15	0.74	0.57, 0.96	0.64	0.48, 0.84	0.54	0.40, 0.71	< 0.001
Multivariable HR (95% CI) ³	1.00	0.89	0.69, 1.14	0.73	0.55, 0.96	0.64	0.47, 0.87	0.57	0.40, 0.80	< 0.001
Myocardial infarction										
No. of case	133	122		101		90		78		
Age- and sex-adjusted HR (95% CI)	1.00	0.90	0.70, 1.15	0.77	0.58, 1.00	0.65	0.49, 0.87	0.55	0.41, 0.74	< 0.001
Multivariable HR (95% CI) ¹	1.00	0.89	0.69, 1.15	0.76	0.58, 1.00	0.65	0.49, 0.86	0.54	0.40, 0.73	< 0.001
Multivariable HR (95% CI) ²	1.00	0.90	0.68, 1.19	0.74	0.55, 1.01	0.63	0.46, 0.87	0.53	0.38, 0.74	< 0.001
Multivariable HR (95% CI) ³	1.00	0.88	0.66, 1.17	0.73	0.53, 1.00	0.63	0.44, 0.90	0.56	0.37, 0.82	0.001
Heart failure										
No. of case	103	118		107		117		119		
Age- and sex-adjusted HR (95% CI)	1.00	0.91	0.69, 1.19	0.80	0.60, 1.06	0.80	0.60, 1.05	0.78	0.59, 1.03	0.06
Multivariable HR (95% CI) ¹	1.00	0.90	0.69, 1.18	0.80	0.60, 1.06	0.81	0.61, 1.07	0.79	0.60, 1.04	0.34
Multivariable HR (95% CI) ²	1.00	0.91	0.67, 1.23	0.77	0.56, 1.06	0.78	0.57, 1.07	0.75	0.55, 1.04	0.27
Multivariable HR (95% CI) ³	1.00	0.87	0.64, 1.18	0.69	0.49, 0.97	0.67	0.47, 0.96	0.65	0.45, 0.96	0.13

¹Adjusted for age, sex, and socio-economic status (educational status).

²Adjusted for age, sex, socio-economic status (educational status), and health behaviours (hours of walking, hours of sports, ethanol intake and smoking status).

³A full model with adjustment for age, sex, educational status, hours of walking, hours of sports, ethanol intake, smoking status, history of hypertension and diabetes, BMI, perceived mental stress, multivitamin supplementation, quintiles of energy-adjusted Na and SFA intakes and total energy intakes.

inhibiting pro-atherogenic chemokines and enhancing serum levels of adiponectin⁽²⁶⁾. Moreover, an antihypertensive effect of vitamin B₃ was also suggested⁽³⁰⁾.

We observed that a higher dietary vitamin B₁ intake was associated with reduced risk of mortality from heart failure. Vitamin B₁ deficiency was commonly considered to be correlated with a failing heart. In a meta-analysis of nine observational studies, the prevalence of vitamin B₁ deficiency was higher with an OR of 2.5

(95 % CI 1.7, 3.9) in heart failure group than in control⁽³¹⁾. Also known as wet beriberi or cardiac beriberi, vitamin B₁ deficiency was characterised by peripheral neuropathy and muscle weakness resulting in heart failure⁽³⁾. The vitamin B₁ deficiency-related heart failure was attributed to the vitamin B₁ role in energy metabolism⁽³⁾. Some studies reported that vitamin B₁ supplementation had beneficial effects on cardiac function⁽⁶⁾, but the evidence is still inconclusive⁽³⁾.

Table 3. CVD mortality according to quintiles of vitamin B₃ intake (Hazard ratios and 95 % confidence intervals)

	Q1 (low)	Q2		Q3		Q4		Q5 (high)		<i>P</i> _{for trend}
		HR	95 % CI	HR	95 % CI	HR	95 % CI	HR	95 % CI	
Total <i>n</i>	11 660	11 661		11 660		11 661		11 660		
Person-years	180 265	187 575		194 533		197 250		200 601		
CVD										
No. of case	715	658		663		649		686		
Age- and sex-adjusted HR (95% CI)	1.00	0.89	0.80, 0.99	0.88	0.79, 0.98	0.85	0.76, 0.94	0.86	0.77, 0.95	0.004
Multivariable HR (95% CI) ¹	1.00	0.89	0.80, 0.99	0.88	0.79, 0.98	0.84	0.75, 0.94	0.85	0.77, 0.95	0.004
Multivariable HR (95% CI) ²	1.00	0.93	0.83, 1.05	0.92	0.82, 1.03	0.87	0.78, 0.99	0.88	0.78, 1.00	0.03
Multivariable HR (95% CI) ³	1.00	0.92	0.82, 1.04	0.91	0.81, 1.03	0.88	0.78, 0.99	0.90	0.80, 1.03	0.13
Stroke										
No. of case	316	268		309		311		300		
Age- and sex-adjusted HR (95% CI)	1.00	0.82	0.69, 0.97	0.93	0.79, 1.09	0.92	0.78, 1.08	0.85	0.72, 1.00	0.17
Multivariable HR (95% CI) ¹	1.00	0.81	0.69, 0.96	0.92	0.78, 1.08	0.91	0.77, 1.07	0.84	0.71, 0.99	0.08
Multivariable HR (95% CI) ²	1.00	0.90	0.75, 1.07	1.02	0.85, 1.21	1.00	0.84, 1.19	0.93	0.77, 1.11	0.46
Multivariable HR (95% CI) ³	1.00	0.87	0.73, 1.04	0.98	0.82, 1.17	0.97	0.80, 1.16	0.91	0.75, 1.10	0.38
Haemorrhagic stroke										
No. of case	138	94		104		101		112		
Age- and sex-adjusted HR (95% CI)	1.00	0.63	0.49, 0.83	0.68	0.52, 0.88	0.64	0.49, 0.83	0.68	0.52, 0.88	0.009
Multivariable HR (95% CI) ¹	1.00	0.63	0.49, 0.83	0.67	0.52, 0.88	0.64	0.49, 0.83	0.67	0.52, 0.88	0.01
Multivariable HR (95% CI) ²	1.00	0.69	0.52, 0.91	0.74	0.55, 0.98	0.69	0.52, 0.93	0.73	0.55, 0.98	0.13
Multivariable HR (95% CI) ³	1.00	0.67	0.50, 0.89	0.71	0.53, 0.95	0.68	0.50, 0.92	0.74	0.55, 1.01	0.16
Ischaemic stroke										
No. of case	155	139		179		182		162		
Age- and sex-adjusted HR (95% CI)	1.00	0.87	0.69, 1.10	1.13	0.91, 1.41	1.12	0.90, 1.40	0.96	0.77, 1.21	0.67
Multivariable HR (95% CI) ¹	1.00	0.86	0.68, 1.09	1.11	0.89, 1.38	1.11	0.89, 1.38	0.95	0.76, 1.20	0.98
Multivariable HR (95% CI) ²	1.00	0.95	0.75, 1.22	1.23	0.97, 1.56	1.21	0.95, 1.55	1.05	0.81, 1.35	0.69
Multivariable HR (95% CI) ³	1.00	0.92	0.72, 1.18	1.17	0.92, 1.50	1.17	0.91, 1.50	1.01	0.77, 1.32	0.96
Ischaemic heart disease										
No. of case	174	149		136		115		125		
Age- and sex-adjusted HR (95% CI)	1.00	0.89	0.71, 1.11	0.81	0.64, 1.02	0.68	0.53, 0.86	0.71	0.56, 0.90	< 0.001
Multivariable HR (95% CI) ¹	1.00	0.88	0.71, 1.10	0.80	0.64, 1.01	0.67	0.53, 0.86	0.71	0.56, 0.90	0.001
Multivariable HR (95% CI) ²	1.00	0.88	0.70, 1.12	0.80	0.62, 1.02	0.66	0.51, 0.86	0.69	0.53, 0.90	0.002
Multivariable HR (95% CI) ³	1.00	0.90	0.71, 1.15	0.84	0.65, 1.08	0.72	0.55, 0.95	0.79	0.60, 1.04	0.05
Myocardial infarction										
No. of case	134	119		95		86		90		
Age- and sex-adjusted HR (95% CI)	1.00	0.93	0.72, 1.20	0.75	0.57, 0.98	0.67	0.51, 0.89	0.68	0.51, 0.89	< 0.001
Multivariable HR (95% CI) ¹	1.00	0.93	0.72, 1.19	0.74	0.57, 0.97	0.67	0.50, 0.88	0.68	0.51, 0.89	< 0.001
Multivariable HR (95% CI) ²	1.00	0.92	0.70, 1.20	0.72	0.54, 0.96	0.64	0.47, 0.87	0.64	0.48, 0.87	0.001
Multivariable HR (95% CI) ³	1.00	0.91	0.70, 1.20	0.72	0.54, 0.97	0.65	0.48, 0.88	0.66	0.48, 0.90	0.02
Heart failure										
No. of case	103	119		114		99		129		
Age- and sex-adjusted HR (95% CI)	1.00	1.03	0.79, 1.35	0.96	0.73, 1.27	0.81	0.61, 1.07	1.01	0.77, 1.31	0.60
Multivariable HR (95% CI) ¹	1.00	1.02	0.78, 1.34	0.95	0.73, 1.25	0.80	0.60, 1.06	1.00	0.76, 1.31	0.81
Multivariable HR (95% CI) ²	1.00	1.04	0.78, 1.39	0.95	0.71, 1.28	0.79	0.58, 1.07	0.97	0.72, 1.31	0.97
Multivariable HR (95% CI) ³	1.00	1.03	0.77, 1.38	0.95	0.70, 1.28	0.79	0.57, 1.08	0.97	0.71, 1.33	0.88

¹Adjusted for age, sex and socio-economic status (educational status).

²Adjusted for age, sex, socio-economic status (educational status) and health behaviours (hours of walking, hours of sports, ethanol intake and smoking status).

³A full mode with adjustment for age, sex, educational status, hours of walking, hours of sports, ethanol intake, smoking status, history of hypertension and diabetes, smoking status, BMI, hours of walking, hours of sports, educational status, perceived mental stress, ethanol intake, multivitamin supplementation, quintiles of energy-adjusted Na and SFA intakes and total energy intakes.

The dietary intake of vitamin B₃ in our study tended to associate with a lower risk of mortality from haemorrhagic stroke. In a case-control study including sixty-nine stroke cases and sixty-nine controls, vitamin B₃ was found to be inversely correlated with risk of stroke (OR: 0.17; 95 % CI 0.04, 0.82)⁽³²⁾. However, some meta-analyses concluded that vitamin B₃ had similar protective effects on both CHD and stroke outcomes^(9,25), while

others failed to find protective effects against stroke^(26,27). The available studies and meta-analyses did not comment on the effect of vitamin B₃ on stroke subtypes. Vitamin B₃ was shown to reduce the blood pressure, an important risk factor for haemorrhagic stroke⁽³⁰⁾. On the other hand, vitamin B₃ may promote vascular plasticity after an acute attack of stroke. In an animal experiment, Niaspan treatment of stroke in rats with diabetes

promoted vascular remodelling and improved functional outcome⁽³³⁾. Therefore, an impact of vitamin B₃ on risk of haemorrhagic stroke mortality could be plausible.

To the best of our knowledge, this is the first study to investigate the association of dietary intakes of vitamins B₁ and B₃ with the risk of mortality from CVD among Japanese population. The JACC study is a large, nationwide, community-based, prospective Japanese cohort study. The large sample size allowed us to investigate the associations of quintile categories of dietary vitamins B₁ and B₃ intakes with the risks of type-specific cardiovascular mortality as well as total CVD in Japanese population. Other strengths of this study included the prospective study design, the utilisation of a validated FFQ, the consistent endpoint determination and the exclusion of participants with CVD and cancer before the starting point of follow-up.

Limitations of this study mainly originate from the dietary assessment. The one-time measurement of dietary intakes cannot completely represent the consumption of nutrients during a long-term follow-up. The exclusion of 18 428 non-respondents to FFQ might result in a selection bias. Compared with 24 614 non-respondents to FFQ, the 61 787 respondents were more likely to be young and more educated (online Supplementary Table S2). Several research of the JACC study reported the underestimation of nutrients intakes, which could be attributed to the limited number of food items in the used FFQ. Second, we had no data about the exact amounts or types of vitamin supplementation. To our knowledge, in the past century, vitamin supplementation was not common among Japanese population; thus, we believe that it would not affect the result substantially. In this study, approximately 88 % of participants did not use any vitamin supplementation and only 3 % used it on daily basis. The exclusion of daily supplementation uses did not change the result. Third, in Japan, the accuracy of heart failure death certificate diagnosis is a questionable issue. It is generally believed that heart failure death was overestimated before 1994, because most deaths of unknown origin such as cardiac arrest or arrhythmic death were more likely diagnosed as unspecific heart failure⁽³⁴⁾. Therefore, approximately 27–50 % heart failure deaths were accounted for this misclassification⁽³⁴⁾. Lastly, we did not have data on biomarkers of atherosclerosis and endothelial dysfunction, lipid metabolism and systematic inflammation such as C-reactive protein, lipoprotein-associated phospholipase A2, pro-atherogenic chemokines or serum levels of adiponectin and cannot determine all confounding effects from some other nutrients, lifestyles and socio-economic factors.

Conclusions

In this prospective cohort study, higher dietary intakes of vitamins B₁ and B₃ were inversely associated with a reduced risk of mortality from CVD among Japanese men and women. Dietary intakes of these vitamins from their food sources are available, accessible, affordable, safe and more acceptable by the general population than supplementary intakes. Therefore, dietary intakes of food rich in these vitamins could be encouraged for decreasing the risk of CVD mortality. However, our findings warrant further studies in different populations.

Acknowledgements

The authors thank Dr. Kunio Aoki, Professor Emeritus, Nagoya, University School of Medicine and the former Chairman of the JACC Study, and Dr. Haruo Sugano, the former Director of the Cancer Institute, Tokyo, who greatly contributed to the initiation of the JACC study. The authors also thank all staff members involved in this study for their valuable help in conducting the baseline survey and follow-up.

This study has been supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) (MonbuKagaku-sho); Grants-in-Aid for Scientific Research on Priority Areas of Cancer and Grants-in-Aid for Scientific Research on Priority Areas of Cancer Epidemiology from MEXT (nos. 61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, 11181101, 17015022, 18014011, 20014026, 20390156, 26293138), and JSPS KAKENHI No.16H06277. This research was also supported by Grant-in-Aid from the Ministry of Health, Labour and Welfare, Health and Labor Sciences research grants, Japan (Comprehensive Research on Cardiovascular Disease and Life-Style Related Diseases: H20–Junkankitou (Seishuu)–Ippan–013; H23–Junkankitou (Seishuu)–Ippan–005); an Intramural Research Fund (22–4–5) for Cardiovascular Diseases of National Cerebral and Cardiovascular Center; Comprehensive Research on Cardiovascular Diseases and Life-Style Related Diseases (H26–Junkankitou (Seisaku)–Ippan–001) and H29–Junkankitou (Seishuu)–Ippan–003 and 20FA1002.

C. T. designed the study, analysed the data and wrote the manuscript. E. S. E. and H. I. conducted the technique review and reviewed and edited the manuscript. K. S. and A. T. made critical revisions of the manuscript. C. T. and H. I. had primary responsibility for final content. All authors read and approved the final manuscript.

The authors have no conflict of interest to declare.

Supplementary material

For supplementary material referred to in this article, please visit <https://doi.org/10.1017/S0007114522001209>

References

1. Mikkelsen K & Apostolopoulos V (2018) B Vitamins and Ageing. *Subcell Biochem* **90**, 451–470.
2. Suzuki N, Goto Y, Ota H, *et al.* (2018) Characteristics of the Japanese Diet described in epidemiologic publications: a qualitative systematic review. *J Nutr Sci Vitaminol (Tokyo)* **64**, 129–137.
3. Eshak ES & Arafa AE (2018) Thiamine deficiency and cardiovascular disorders. *Nutr Metab Cardiovasc Dis* **28**, 965–972.
4. Crook MA (2014) The importance of recognizing pellagra (niacin deficiency) as it still occurs. *Nutrition* **30**, 729–730.
5. Yamada Y, Kusakari Y, Akaoka M, *et al.* (2020) Thiamine treatment preserves cardiac function against ischemia injury via maintaining mitochondrial size and ATP levels. *J Appl Physiol* **130**, 26–35.
6. Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, *et al.* (2012) Thiamine supplementation in symptomatic chronic

- heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. *Clin Res Cardiol* **101**, 159–164.
7. McKenney J (2004) New perspectives on the use of niacin in the treatment of lipid disorders. *Arch Intern Med* **164**, 697–705.
 8. Linder K, Willmann C, Kantartzis K, *et al.* (2019) Dietary niacin intake predicts the decrease of liver fat content during a lifestyle intervention. *Sci Rep* **9**, 1303.
 9. Bruckert E, Labreuche J & Amarenco P (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. *Atherosclerosis* **210**, 353–361.
 10. Wexler BC & Lutmer RF (1973) Changes in myocardial thiamine in arteriosclerotic and non-arteriosclerotic rats subjected to isoprenaline induced myocardial infarction. *Br J Exp Pathol* **54**, 479–491.
 11. Freye E (1976) Cardiovascular effects of high doses of thiamine (vitamin B₁) in the dog with special reference to myocardial oxygen consumption. *Basic Res Cardiol* **71**, 192–198.
 12. Canner PL, Berge KG, Wenger NK, *et al.* (1986) Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. *J Am Coll Cardiol* **8**, 1245–1255.
 13. Schandelmaier S, Briel M, Saccilotto R, *et al.* (2017) Niacin for primary and secondary prevention of cardiovascular events. *Cochrane Database Syst Rev* **6**, Cd009744.
 14. Yamagishi K, Iso H, Date C, *et al.* (2008) Fish, *n*-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. *J Am Coll Cardiol* **52**, 988–996.
 15. Nagura J, Iso H, Watanabe Y, *et al.* (2009) Fruit, vegetable and bean intake and mortality from cardiovascular disease among Japanese men and women: the JACC Study. *Br J Nutr* **102**, 285–292.
 16. Shibata K, Fukuwatari T, Imai E, *et al.* (2012) Dietary reference intakes for Japanese 2010: water-soluble vitamins. *J Nutr Sci Vitaminol* **59**, S67–S82.
 17. Tamakoshi A, Ozasa K, Fujino Y, *et al.* (2013) Cohort profile of the Japan Collaborative Cohort Study at final follow-up. *J Epidemiol* **23**, 227–232.
 18. Date C, Fukui M, Yamamoto A, *et al.* (2005) Reproducibility and validity of a self-administered food frequency questionnaire used in the JACC study. *J Epidemiol* **15**, S9–S23.
 19. Hirokadzu T (2001) Standard tables of food composition in Japan, fifth revised edition. *Nippon Shokubun Kagaku Kagaku Kaishi* **48**, 549–553.
 20. Watanabe T, Suzuki A, Hagiwara K, *et al.* (2002) Food composition table for calculation of nutrient contents considering changes in weight induced by cooking. *J Jpn Soc Nutr Food Science* **55**, 165–176.
 21. Hernando F & Maria C (1987) Nutrient Intake Data Calculated using Food Composition Tables: Factors Affecting Accuracy. <https://archive.unu.edu/unupress/unupbooks/80633e/80633E0g.htm> (accessed January 2022).
 22. Eshak ES, Iso H, Muraki I, *et al.* (2019) Among the water-soluble vitamins, dietary intakes of vitamins C, B₁ and folate are associated with the reduced risk of diabetes in Japanese women but not men. *Br J Nutr* **121**, 1357–1364.
 23. Arora S, Lidor A, Abularrage CJ, *et al.* (2006) Thiamine (vitamin B₁) improves endothelium-dependent vasodilatation in the presence of hyperglycemia. *Ann Vasc Surg* **20**, 653–658.
 24. Stirban A, Nandreas S, Kirana S, *et al.* (2012) Benfotiamine counteracts smoking-induced vascular dysfunction in healthy smokers. *Int J Vasc Med* **2012**, 968761.
 25. D'Andrea E, Hey SP, Ramirez CL, *et al.* (2019) Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis. *JAMA Netw Open* **2**, e192224.
 26. Lavigne PM & Karas RH (2013) The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. *J Am Coll Cardiol* **61**, 440–446.
 27. Garg A, Sharma A, Krishnamoorthy P, *et al.* (2017) Role of niacin in current clinical practice: a systematic review. *Am J Med* **130**, 173–187.
 28. Thornalley PJ, Babaei-Jadidi R, Al Ali H, *et al.* (2007) High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. *Diabetologia* **50**, 2164–2170.
 29. Avena R, Arora S, Carmody BJ, *et al.* (2000) Thiamine (Vitamin B₁) protects against glucose- and insulin-mediated proliferation of human infragenicular arterial smooth muscle cells. *Ann Vasc Surg* **14**, 37–43.
 30. Bays HE, Maccubbin D, Meehan AG, *et al.* (2009) Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. *Clin Ther* **31**, 115–122.
 31. Jain A, Mehta R, Al-Ani M, *et al.* (2015) Determining the role of thiamine deficiency in systolic heart failure: a meta-analysis and systematic review. *J Card Fail* **21**, 1000–1007.
 32. Park Y (2010) Intakes of vegetables and related nutrients such as vitamin B complex, potassium, and calcium, are negatively correlated with risk of stroke in Korea. *Nutr Res Pract* **4**, 303–310.
 33. Ye X, Chopp M, Cui X, *et al.* (2011) Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats. *Exp Neurol* **232**, 299–308.
 34. Eshak ES, Iso H, Yamagishi K, *et al.* (2018) Dietary intakes of fat soluble vitamins as predictors of mortality from heart failure in a large prospective cohort study. *Nutrition* **47**, 50–55.